Skip to main content
Premium Trial:

Request an Annual Quote

Avanticell to Lead Scottish Consortium in 3D Cell-based Assays Effort

NEW YORK (GenomeWeb News) – Avanticell Science said yesterday that it will head a consortium that includes Giltech and Culzean Medical Devices in developing three-dimensional cell-based assay systems for drug discovery research.

Avanticell specializes in cell culture products and services, Culzean Medical Devices designs and makes implantable medical products, and Giltech makes biomaterials and biodegradable products.

The two-year, £1 million ($2 million) project is being co-funded by the Technology Strategy Board, an entity set up by the Scottish government to promote technological innovation.

The companies will work together to “put living cells into a three-dimensional scaffold to create this new generation of three-dimensional cell-based assays,” the company said. Current cell-based assays are limited because they use conventional flat layers of cell cultures and three-dimensional cell cultures are “much more likely” to resemble human cells, it added.

“The project will result in the next generation of cell-based assays, accelerating and reducing the cost of new drug development to treat life-threatening diseases such as cancer,” Avanticell CEO Jo Oliver said in a statement.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.